Valuation: Talphera, Inc.

Market Cap 57.62M 51.43M 47.98M 43.59M 82.12M 5.57B 82.76M 576M 225M 2.83B 216M 212M 9.1B P/E 2026 *
-5.12x
P/E 2027 * -5.1x
Enterprise Value 57.62M 51.43M 47.98M 43.59M 82.12M 5.57B 82.76M 576M 225M 2.83B 216M 212M 9.1B EV / Sales 2026 *
-
EV / Sales 2027 * 129x
Free-Float
78.59%
Yield 2026 *
-
Yield 2027 * -
1 day-5.41%
1 week-10.26%
Current month-9.48%
1 month-12.50%
3 months-11.02%
6 months+43.62%
Current year-7.89%
1 week 1.05
Extreme 1.05
1.19
1 month 1.05
Extreme 1.05
1.26
Current year 0.69
Extreme 0.6866
1.5
1 year 0.69
Extreme 0.6866
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
21
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 2017-03-05
Director of Finance/CFO 56 2017-07-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 60 2006-07-31
Director/Board Member 72 2010-01-31
Chairman 75 2013-02-10
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 Tax

Chief Technology Officer

-4,518 0.0090%
4/2/26 Tax

Chief Executive Officer

9,938 0.0199%
4/2/26 Tax

Chief Technology Officer

2,444 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-5.41%-10.26%-4.55%+71.29% 57.62M
+2.70%+0.35%+40.67%+110.31% 1,032B
+1.44%-3.41%+37.36%+63.95% 614B
+1.75%+3.07%+17.89%+83.05% 471B
+0.60%-4.35%+60.80%+37.46% 350B
+2.92%+3.06%+24.83%+45.10% 337B
+2.42%-0.74%+13.44%+35.80% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.60%-2.49%+40.45%+54.44% 218B
+1.82%-2.93%+29.29%+96.48% 179B
Average +0.59%-3.30%+25.55%+61.01% 371.49B
Weighted average by Cap. +0.71%-3.18%+32.16%+70.59%

Financials

2026 *2027 *
Net sales - 447K 399K 372K 338K 637K 43.25M 642K 4.47M 1.75M 21.99M 1.68M 1.64M 70.63M
Net income -15.61M -13.93M -13M -11.81M -22.25M -1.51B -22.42M -156M -60.97M -768M -58.6M -57.32M -2.47B -18.63M -16.63M -15.52M -14.1M -26.56M -1.8B -26.76M -186M -72.79M -917M -69.95M -68.44M -2.94B
Net Debt - -
Projected Income Statement - Annual - Talphera, Inc.
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
26-10-07 US$1.050 -5.41% 270,121
26-10-06 US$1.110 -4.31% 115,787
26-10-05 US$1.160 +2.65% 587,121
26-10-02 US$1.130 +0.89% 345,050
26-10-01 US$1.120 -3.45% 106,401
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Talphera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.050USD
Average target price
3.125USD
Spread / Average Target
+197.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Talphera, Inc.
  1. Stock Market
  2. Stocks
  3. TLPH Stock